Is there a correlation between tumor marker panel and tumor size and histopathology in well staged patients with borderline ovarian tumors?

Acta Obstetricia et Gynecologica Scandinavica

Volumn 86, Issue 4, 2007, Pages 484-490

  Ayhan, Ali ^a   Guven, Suleyman ^a,b   Guven, Emine Seda Guvendag ^a   Kucukali, Turkan ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

^b NONE   (Turkey)

Author keywords

Borderline ovarian tumors; CA 125 antigen; CA 15 3 antigen; CA 19 9 antigen; CEA

Indexed keywords

CA 125 ANTIGEN; CA 15-3 ANTIGEN; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HISTOLOGY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; OVARY TUMOR; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY; STATISTICAL SIGNIFICANCE; TUMOR DIAGNOSIS; TUMOR VOLUME;

ADENOCARCINOMA, MUCINOUS; ADULT; AGED; CA-125 ANTIGEN; CA-15-3 ANTIGEN; CA-19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CYSTADENOCARCINOMA, SEROUS; FEMALE; HUMANS; LOGISTIC MODELS; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 34248583159     PISSN: 00016349     EISSN: 16000412     Source Type: Journal    
DOI: 10.1080/00016340701226138     Document Type: Article

References (19)

1. Barakat RR. Borderline tumors of the ovary. Obstet Gynecol Clin North Am. 1994;21:93-105.
2. Manchul LA, Simm J, Levin W, et al. Borderline epithelial ovarian tumors: a review of 81 cases with an assessment of the impact of treatment. Int J Radiat Oncol Biol Phys. 1992;22:867-74.
3. Rice LW, Lage JM, Berkowitz RS, et al. Preoperative serum CA-125 levels in borderline tumors of the ovary. Gynecol Oncol. 1992;46:226-9.
4. Ochiai K, Shinozaki H, Takada A, et al. A retrospective study of 1069 epithelial borderline malignancies of the ovary treated in Japan. Proc Ann Meet Am Soc Clin Oncol. 1998;17:A1429.
5. Tamakoshi K, Kikkawa F, Shibata K, et al. Clinical value of CA125, CA19-9, CEA, CA72-4, and TPA in borderline ovarian tumor. Gynecol Oncol. 1996;62:67-72.
6. Massad LS Jr, Hunter VJ, Szpak CA, Clarke-Pearson DL, Creasman WT. Epithelial ovarian tumors of low malignant potential. Obstet Gynecol. 1991;78:1027-32.
7. International Federation of Gynecology and Obstetrics. Changes in definitions of clinical staging for carcinoma of the cervix and ovary. Am J Obstet Gynecol. 1987;156:263-4.
8. van Haaften-Day C, Shen Y, Xu F, et al. OVX1, macrophagecolony stimulating factor, and CA-125-II as tumor markers for epithelial ovarian carcinoma: a critical appraisal. Cancer. 2001;92:2837-44.
9. Gotlieb WH, Soriano D, Achiron R, et al. CA 125 measurement and ultrasonography in borderline tumors of the ovary. Am J Obstet Gynecol. 2000;183:541-6.
10. Engelen MJ, de Bruijn HW, Hollema H, et al. Serum CA 125, carcinoembryonic antigen, and CA 19-9 as tumor markers in borderline ovarian tumors. Gynecol Oncol. 2000;78:16-20.
11. Zanetta G, Rota S, Lissoni A, Meni A, Brancatelli G, Buda A. Ultrasound, physical examination, and CA 125 measurement for the detection of recurrence after conservative surgery for early borderline ovarian tumors. Gynecol Oncol. 2001;81:63-6.
12. But I. Serum CA 125 level as a reflection of proliferative activity of serous borderline ovarian tumor. Int J Gynaecol Obstet. 2000;71:289-91.
13. de Bruijn HW, van der Zee AG, Aalders JG. The value of cancer antigen 125 (CA 125) during treatment and follow-up of patients with ovarian cancer. Curr Opin Obstet Gynecol. 1997;9:8-13.
14. Motoyama T, Watanabe H, Takeuchi S, Watanabe T, Gotoh S, Okazaki E. Cancer antigen 125, carcinoembryonic antigen, and carbohydrate determinant 19-9 in ovarian tumors. Cancer. 1990;66:2628-35.
15. Stall KE, Martin EW Jr. Plasma carcinoembryonic antigen levels in ovarian cancer patients: a chart review and survey of published data. J Reprod Med. 1981;26:73-9.
16. Schutter EM, Davelaar EM, van Kamp GJ, Verstraeten RA, Kenemans P, Verheijen RH. The differential diagnostic potential of a panel of tumor markers (CA 125, CA 15-3, and CA 72-4 antigens) in patients with a pelvic mass. Am J Obstet Gynecol. 2002;187:385-92.
17. Yedema KA, Kenemans P, Wobbes T, et al. Carcinoma-associated mucin serum markers CA M26 and CA M29: efficacy in detecting and monitoring patients with cancer of the breast, colon, ovary, endometrium and cervix. Int J Cancer. 1991;47:170-9.
18. Gadducci A, Cosio S, Carpi A, Nicolini A, Genazzani AR. Serum tumor markers in the management of ovarian, endometrial and cervical cancer. Biomed Pharmacother. 2004;58:24-38.
19. Shen-Gunther J, Mannel RS. Ascites as a predictor of ovarian malignancy. Gynecol Oncol. 2002;87:77-83.